New approaches and potential treatments for dry age-related macular degeneration

Arquivos Brasileiros de Oftalmologia

Volumn 75, Issue 1, 2012, Pages 71-76

  Damico, Francisco Max ^a   Gasparin, Fabio ^a   Scolari, Mariana Ramos ^a   Pedral, Lycia Sampaio ^b   Takahashi, Beatriz Sayuri ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

Author keywords

Complement activation; Inflammation; Macular degeneration drug therapy; Retina; Retinal pigment epithelium

Indexed keywords

ANIMAL; CLINICAL TRIAL (TOPIC); COMPLEMENT ALTERNATIVE PATHWAY; DRUG EFFECT; HUMAN; RETINA MACULA DEGENERATION; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; COMPLEMENT PATHWAY, ALTERNATIVE; HUMANS; MACULAR DEGENERATION;

EID: 84867148658     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492012000100016     Document Type: Review

References (52)

1. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48(3):257-93.
2. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. Epidemiology of age-related maculopathy: a review. Eur J Epidemiol. 2003;18(9):845-54.
3. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114(2):253-62.
4. o 8. Arch Ophthalmol. 2001;119(10):1417-36. Erratum in: Arch Ophthalmol. 2008;126(9):1251.
5. o 9. Arch Ophthalmol. 2001;119(10):1439-52. Erratum in: Arch Ophthalmol. 2008;126(9):1251.
6. Fliesler SJ, Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res. 1983;22(2):79-131.
7. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 2004;122(4):598-614.
8. Holz FG, Bellman C, Staudt S, Schütt F, Völcker HE. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2001;42(5):1051-6.
9. Zhou J, Jang YP, Kim SR, Sparrow JR. Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci U S A. 2006;103(44):16182-7.
10. Radu RA, Hu J, Yuan Q, Welch DL, Makshanoff J, Lloyd M, et al. Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration. J Biol Chem. 2011;286(21):18593-601.
11. Haddad S, Chen CA, Santangelo SL, Seddon JM. The genetics of age-related macular degeneration: a review of progress to date. Surv Ophthalmol. 2006;51(4):316-63.
12. Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res. 2000;70(4):441-9.
13. Buschini E, Piras A, Nuzzi R, Vercelli A. Age related macular degeneration and drusen: neuroinflammation in the retina. Prog Neurobiol. 2011;95(1):14-25.
14. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20(6):705-32.
15. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pa thogenesis of age-related macular degeneration. Surv Ophthalmol. 2006;51(2):137-52.
16. Vingerling JR, Dielemans I, Bots ML, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J Epidemiol. 1995;142(4):404-9.
17. McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology. 1992;42(2):447-9.
18. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99(18):11830-5.
19. Burns RP, Feeney-Burns L. Clinico-morphologic correlations of drusen of Bruch's mem brane. Trans Am Ophthalmol Soc. 1980;78:206-25.
20. Löffler KU, Lee WR. Basal linear deposit in the human macula. Graefes Arch Clin Exp Ophthalmol. 1986;224(6):493-501.
21. Penfold PL, Killingsworth MC, Sarks SH. Senile macular degeneration: the involvement of immunocompetent cells. Graefes Arch Clin Exp Ophthalmol. 1985;223(2):69-76.
22. van der Schaft TL, Mooy CM, de Bruijn WC, de Jong PT. Early stages of age-related macular degeneration: an immunofluorescence and electron microscopy study. Br J Ophthalmol. 1993;77(10):657-61.
23. Grindle CFJ, Marshall J. Ageing changes in Bruch's membrane and their functional implications. Trans Ophthalmol Soc U K. 1978;98(1):172-5.
24. Faktorovich EG, Steinberg RH, Yasumura D, Matthes MT, LaVail MM. Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor. Nature. 1990;347(6288):83-6.
25. LaVail MM, Yasumura D, Matthes MT, Lau-Villacorta C, Unoki K, Sung CH, et al. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci. 1998;39(3):592-602.
26. Tao W, Wen R, Goddard MB, Sherman SD, O'Rourke PJ, Stabila PF, et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2002;43(10):3292-8.
27. LaVail MM, Unoki K, Yasumura D, Matthes MT, Yancopoulos GD, Steinberg RH. Multi- ple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc Natl Acad Sci U S A. 1992;89(23):11249-53.
28. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A. 2006;103(10):3896-901.
29. Zhang K, Hopkins JJ, Heier JS, Birch DG, Halperin LS, Albini TA, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geo graphic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108(15):6241-5.
30. Woldemussie E, Wijono M, Pow D. Localization of alpha 2 receptors in ocular tissues. Vis Neurosci. 2007;24(5):745-56.
31. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol. 1996;41 Suppl 1:S9-18.
32. Lai RK, Chun T, Hasson D, Lee S, Mehrbod F, Wheeler L. Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat. Vis Neurosci. 2002;19(2):175-85.
33. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42(12):2849-55.
34. Tatton W, Chen D, Chalmers-Redman R, Wheeler L, Nixon R, Tatton N. Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation. Surv Ophthalmol. 2003;48 Suppl 1:25-37.
35. Donello JE, Padillo EU, Webster ML, Wheeler LA, Gil DW. alpha(2)-Adrenoceptor agonis ts inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther. 2001;296(1):216-23.
36. Collier RJ, Wang Y, Smith SS, Martin E, Ornberg R, Rhoades K, et al. Complement deposition and microglial activation in the outer retina in light-induced retinopathy: inhibition by a 5-HT1A agonist. Invest Ophthalmol Vis Sci. 2011;52(11):8108-16.
37. Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology. 2002;59(6):802-8.
38. Landa G, Butovsky O, Shoshani J, Schwartz M, Pollack A. Weekly vaccination with Co paxone (glatiramer acetate) as a potential therapy for dry age-related macular de generation. Curr Eye Res. 2008;33(11):1011-3.
39. Landa G, Rosen RB, Patel A, Lima VC, Tai KW, Perez VR, et al. Qualitative spectral OCT/ SLO analysis of drusen change in dry age-related macular degeneration patients treated with Copaxone. J Ocul Pharmacol Ther. 2011;27(1):77-82.
40. Ding JD, Johnson LV, Herrmann R, Farsiu S, Smith SG, Groelle M, et al. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108(28):E279-87.
41. Radu RA, Han Y, Bui TV, Nusinowitz S, Bok D, Lichter J, et al. Reductions in serum vi tamin A arrest accumulation of toxic retinal fluorophores: a potential the rapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci. 2005;46(12):4393-401.
42. Mata NL, Tsivkovskaia N, Bui TV. Fenretinide reduces the incidence of choroidal neovascularization in patients with geographic atrophy. Invest Ophthalmol Vis Sci. 2011;52:E-abstract 1652.
43. Vogel R, Slakter J, McLeod K. A phase II, double-Masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in subjects with age-related macular degeneration: Baseline lesion size, characteristics, and preliminary progression data. Invest Ophthalmol Vis Sci. 2009;50: E-abstract 4919.
44. Kubota R, Birch D, David R. Phase 1, dose-escalating study of the safety, tolerability, and pharmacokinetics of ACU-4429 in healthy volunteers. Invest Ophthalmol Vis Sci. 2009;50:E-abstract 5009.
45. Hageman GS, Mullins RF, Russell SR, Johnson LV, Anderson DH. Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells. FASEB J. 1999;13(3):477-84.
46. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000;14(7):835-46.
47. Sakaguchi H, Miyagi M, Shadrach KG, Rayborn ME, Crabb JW, Hollyfield JG. Clusterin is present in drusen in age-related macular degeneration. Exp Eye Res. 2002;74(4):547-9.
48. Ishibashi T, Patterson R, Ohnishi Y, Inomata H, Ryan SJ. Formation of drusen in the human eye. Am J Ophthalmol. 1986;101(3):342-53.
49. Feeney-Burns L, Ellersieck MR. Age-related changes in the ultrastructure of Bruch's membrane. Am J Ophthalmol. 1985;100(5):686-97.
50. Killingsworth MC. Age-related components of Bruch's membrane in the human eye. Graefes Arch Clin Exp Ophthalmol. 1987;225(6):406-12.
51. Glybina IV, Kennedy A, Ashton P, Abrams GW, Iezzi R. Photoreceptor neuroprotection in RCS rats via low-dose intravitreal sustained-delivery of fluocinolone acetonide. Invest Ophthalmol Vis Sci. 2009;50(10):4847-57.
52. Glybina IV, Kennedy A, Ashton P, Abrams GW, Iezzi R. Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats. Invest Ophthalmol Vis Sci. 2010;51(8):4243-52.